KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Revenue (2017 - 2025)

Bionano Genomics' Revenue history spans 7 years, with the latest figure at $7.4 million for Q3 2025.

  • For Q3 2025, Revenue rose 21.31% year-over-year to $7.4 million; the TTM value through Sep 2025 reached $28.7 million, down 13.84%, while the annual FY2024 figure was $30.8 million, 14.79% down from the prior year.
  • Revenue for Q3 2025 was $7.4 million at Bionano Genomics, up from $6.7 million in the prior quarter.
  • Across five years, Revenue topped out at $10.7 million in Q4 2023 and bottomed at $3.2 million in Q1 2021.
  • The 5-year median for Revenue is $7.2 million (2022), against an average of $7.0 million.
  • The largest annual shift saw Revenue skyrocketed 226.23% in 2021 before it plummeted 34.83% in 2024.
  • A 5-year view of Revenue shows it stood at $6.3 million in 2021, then surged by 30.36% to $8.2 million in 2022, then surged by 30.51% to $10.7 million in 2023, then fell by 23.86% to $8.2 million in 2024, then fell by 9.75% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Revenue are $7.4 million (Q3 2025), $6.7 million (Q2 2025), and $6.5 million (Q1 2025).